Format

Send to

Choose Destination
Neurotherapeutics. 2015 Jan;12(1):3-11. doi: 10.1007/s13311-014-0313-y.

β-Amyloid peptides and amyloid plaques in Alzheimer's disease.

Author information

1
Department of Experimental Medical Science, Lund University, Lund, Sweden, gunnar.gouras@med.lu.se.

Abstract

Many lines of evidence support that β-amyloid (Aβ) peptides play an important role in Alzheimer's disease (AD), the most common cause of dementia. But despite much effort the molecular mechanisms of how Aβ contributes to AD remain unclear. While Aβ is generated from its precursor protein throughout life, the peptide is best known as the main component of amyloid plaques, the neuropathological hallmark of AD. Reduction in Aβ has been the major target of recent experimental therapies against AD. Unfortunately, human clinical trials targeting Aβ have not shown the hoped-for benefits. Thus, doubts have been growing about the role of Aβ as a therapeutic target. Here we review evidence supporting the involvement of Aβ in AD, highlight the importance of differentiating between various forms of Aβ, and suggest that a better understanding of Aβ's precise pathophysiological role in the disease is important for correctly targeting it for potential future therapy.

PMID:
25371168
PMCID:
PMC4322079
DOI:
10.1007/s13311-014-0313-y
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Springer Icon for PubMed Central
Loading ...
Support Center